Labcorp reaffirms 2026-2029 outlook, sees 5%-8% revenue CAGR
LH•Long-term outlook reaffirmed
Labcorp reaffirmed its 2026-2029 long-term outlook following CMS preliminary 2027-2029 Clinical Laboratory Fee Schedule rates under PAMA.
- Outlook targets 5%-8% compound annual revenue growth and 8.5%-11.5% compound annual adjusted EPS growth.
- Adjusted operating margin is expected to expand 75-150 basis points by the end of 2029.
- Free cash flow growth is expected to be in line with adjusted earnings.
- Management said it expects to update on the CMS rate impact when it issues 2027 financial guidance in February 2027.
